Skip to main content
Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · IEX Real-Time Price · USD
16.16
-0.53 (-3.18%)
Jul 19, 2024, 4:00 PM EDT - Market closed

Cartesian Therapeutics Revenue

Cartesian Therapeutics had revenue of $25.91M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $5.84M. In the year 2023, Cartesian Therapeutics had annual revenue of $26.00M.

Revenue (ttm)
$25.91M
Revenue Growth
-68.68%
P/S Ratio
13.34
Revenue / Employee
$681,737
Employees
38
Market Cap
345.49M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202326.00M-84.77M-76.53%
Dec 31, 2022110.78M25.70M30.21%
Dec 31, 202185.08M68.48M412.60%
Dec 31, 202016.60M9.92M148.57%
Dec 31, 20196.68M5.77M639.42%
Dec 31, 2018903.00K696.00K336.23%
Dec 31, 2017207.00K-7.88M-97.44%
Dec 31, 20168.08M2.07M34.47%
Dec 31, 20156.01M2.97M97.73%
Dec 31, 20143.04M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
ModivCare 2.78B
Nevro 430.75M
Vanda Pharmaceuticals 177.60M
Xeris Biopharma Holdings 171.36M
Talkspace 162.13M
Kamada 149.55M
AC Immune 16.82M
TScan Therapeutics 14.81M
Revenue Rankings

RNAC News

More News